INC Research Holdings Inc (INCR) reported quarterly earnings results on Thursday, Jul-28-2016. The company said it had a profit of $0.61 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $0.58. The company posted revenue of $258.80 million in the period, compared to analysts expectations of $252.06 million. The company’s revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.47 EPS.
Many Wall Street Analysts have commented on INC Research Holdings Inc. Credit Suisse Initiated INC Research Holdings Inc on Jun 21, 2016 to “Outperform”, Price Target of the shares are set at $51.Shares were Downgraded by Robert W. Baird on May 3, 2016 to ” Neutral” and Lowered the Price Target to $ 51 from a previous price target of $55 .
INC Research Holdings Inc opened for trading at $44.88 and hit $46.42 on the upside on Thursday, eventually ending the session at $44.97, with a gain of 3.21% or 1.4 points. The heightened volatility saw the trading volume jump to 13,66,410 shares. Company has a market cap of $2,438 M.
In a different news, on Jul 18, 2016, Gregory S Rush (Executive VP and CFO) sold 5,917 shares at $41.50 per share price. According to the SEC, on Jul 12, 2016, Alistair Macdonald (Chief Operating Officer) sold 9,468 shares at $40.19 per share price. On Jul 12, 2016, Christopher L Gaenzle (CAO, GC & Sec) sold 21,918 shares at $40.21 per share price, according to the Form-4 filing with the securities and exchange commission.
INC Research Holdings Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company’s segment Clinical Development Services offers a variety of clinical development services including global studies clinical monitoring investigator recruitment patient recruitment data management and study reports. The Company’s segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Company’s segment Global Consulting provides consulting services regarding clinical trial regulatory affairs regulatory consulting services quality assurance audits and pharmacovigilance consulting non-clinical consulting and medical writing consulting.